MRC Increasing Research Impact
•Transferir como PPT, PDF•
1 gostou•1,191 visualizações
MRC Open Council - Cardiff - July 2011
![Humanised antibodies – four decades ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Recomendados
Mais conteúdo relacionado
Semelhante a MRC Increasing Research Impact
Semelhante a MRC Increasing Research Impact (20)
Último
Último (20)
MRC Increasing Research Impact
- 1. Increasing the impact of MRC research Declan Mulkeen Director, Research Programmes July 2011
- 7. Outcomes from funding: 2010
- 8. The MRC pipeline: 2010 Eg Benlysta Eg ICM software
- 12. DCS Case Study: Sodium nitrite for ischaemia-reperfusion injury in myocardial infarction Lundberg et al. 2008
- 15. Research resources: eg patient cohorts ABC – A Bipolar Cohort (Newcastle): 180 London COPD Exacerbation Cohort (UCL): 250 Paediatric-Onset Inflammatory Disease Cohort and Treatment Study (PICTS) (Edinburgh): 450 Pathobiology of Early Arthritis Cohort (QMUL): 300 Type 2 diabetes in childhood (Birmingham): 85 Rapidly Evolving Multiple Sclerosis (Imperial): 200 UK Primary Sjögren’s syndrome Registry (Newcastle): 500 Wessex severe asthma cohort (Southampton) Mitochondrial Disease Patient Cohort (Newcastle; Oxford; MRC CND, London) UK TTP Registry (UCL) Population-based Ankylosing Spondylitis cohort (Swansea)
- 20. Thank you
- 21. MRC translational research funding TSB Basic medical research Prototype discovery and design Pre-clinical development Early clinical trials Late clinical trials Developmental Pathway Funding Scheme Developmental Clinical Studies Targeted initiatives to alleviate bottlenecks Infrastructure/Resources Methodology Training Continued commitment to basic lab, clinical and population research Capacity building NIHR Translational Stem Cell Research Programme Translational Research Support – the “Managed Programme”
- 22. MRC Translational Funding (@ end 2010) Scheme Number Value Number Value Leading Therapeutic Areas Leading Modalities Last 12 months Since Inception Since Inception DPFS 97 c. £33m 21 c. £12m Cancer, Infection, Neurological Small Molecule, Diagnostic Non-Imaging, Protein/Peptide DCS 13 c. £19m 10 c. £14m Cardiovascular, Infection, Stroke Protein/Peptide, Small Molecule, Vaccine TSCRC 17 c. £11m 6 c. £4m Eye, Oral and GI, Inflammatory and Immune System, Musculoskeletal Regenerative Medicine TOTAL 127 c. £64m 37 c. £30m
Notas do Editor
- Medical research, and health related industries – are, if you look across all areas of science, and industry – clear strengths in the UK. Both in bringing benefits of research to patients, and in turning research into economically important industry, the UK has a very good track record. The challenges … we need to do better – competition we need to do it faster and with better productivity – pace of science is accelerating – in some areas, such as pharmaceuticals, the pace of new products emerging is slowing down we need to do it differently – open discovery small mol pharmaceutical model ? stratification of disease and treatment Govt has backed science - high expectations
- Benlysta : First new Lupus drug in 56 years. Was made possible due to a technique called combinatorial antibody libraries developed at MRC’s LMB. In 2009 it was reported as in Phase III trials, in 2010 reported as undergoing marketing authorisation, and we now know that it has been approved by the FDA (March 2011) as the first new treatment for Lupus in 50 years. Estimates of the market for Benlysta have already been published at around $1.9bn. ICM software : This product, used in brain monitoring for neurosurgery and intensive care was developed back in 2006; by 2010 it was being used in 40 centres worldwide.
- - invested in allowing good ideas to develop longer in academia, or with academic / industry partnership – recognising that more is needed to compete for private investment - created better ways of aligning MRC plans with industry … top level forum … and new initiative, in Immunology and Inflammation, where we developed strategy together, best of academic and industry ideas - made sure ideas that need public sector funding can progress smoothly all the way from MRC early phase studies to late phase NIHR HTA programmes - helped to build new capabilities in Universities, responding to industry which does more and more of its research in partnership with Universities - MRCT CTD screening and medicinal chemistry - increased postgrad CASE training positions with industry, and in the last year have made progress in getting more of these into smaller companies - made it easier for companies to work alongside MRC awards – much more flexible rules MICA - taking care not to duplicate what industry is good at, and especially not to recreate in academia, strategies that have failed in industry.
- - invested in allowing good ideas to develop longer in academia, or with academic / industry partnership – recognising that more is needed to compete for private investment - created better ways of aligning MRC plans with industry … top level forum … and new initiative, in Immunology and Inflammation, where we developed strategy together, best of academic and industry ideas - made sure ideas that need public sector funding can progress smoothly all the way from MRC early phase studies to late phase NIHR HTA programmes - helped to build new capabilities in Universities, responding to industry which does more and more of its research in partnership with Universities - MRCT CTD screening and medicinal chemistry - increased postgrad CASE training positions with industry, and in the last year have made progress in getting more of these into smaller companies - made it easier for companies to work alongside MRC awards – much more flexible rules MICA - taking care not to duplicate what industry is good at, and especially not to recreate in academia, strategies that have failed in industry.
- Dr Matt Jones is an MRC Senior Non-Clinical Fellow in the School of Physiology and Pharmacology, University of Bristol. His research into neuronal networks and control of cognitive behaviour is underpinned by a number of productive industrial collaborations. “ I’ve always collaborated with industry,” says Matt. “A range of companies have provided access to the pharmacological tools, disease models and techniques that I need for my research. Ultimately, if you want to have a positive impact on patients, then you need industry’s support.” Indeed, Matt’s first postdoctoral position was at the MRC National Institute for Medical Research , funded by an industrial collaboration grant linking the MRC and Glaxo Wellcome, now GlaxoSmithKline (GSK). It gave him access to early transgenic mouse models of Alzheimer’s disease, an area he was just moving into researching, and Matt remains in touch with those early collaborators. “ I’m less wary of industry than many academics tend to be,” he admits. “Approaches do vary from company to company but common scientific interests and goals mean I’ve always found industrial collaborations invigorating. For non-clinicians, industry can provide a bridge to patient data and they have a much better appreciation of what’s important in the clinic.” After several years at the Massachusetts Institute of Technology , where he learned state-of-the art electrophysiological techniques used to record neuronal network activity during behaviour, Matt returned to the UK in 2006 to start his own lab applying the technique in models of psychiatric disease. His first Principal Investigator position was funded by a Research Councils UK Academic Fellowship alongside an Integrative Pharmacology Fellowship co-funded by the Association of the British Pharmaceutical Industry. “As soon as I got to Bristol,” says Matt, “I contacted everyone I knew in UK industry and said: ‘This is what I’m doing, is it of any interest?’ It’s vital for academics to be proactive.” As a result, Matt has cultivated collaborations with Eli Lilly & Co, Janssen, GSK, Pfizer and others, always driven by scientific need. “I’m fortunate that our research on neural networks and cognition is riding a wave at the moment,” says Matt. “Saying that, it’s not enough just to be in the right place at the right time – you need to know that you are. So a broad network of contacts is vital. It’s an exciting time for me and for the field. But it’s a bleak picture in industry where improved psychiatric treatments are concerned – there are few new drugs in the pipeline and there’s a growing appreciation that companies need to be supporting research into fundamental mechanisms of brain function.” Through his contacts and collaborations, most of the PhD students in Matt’s lab have some involvement with industry through MRC Industrial CASE studentships or similar schemes . “It benefits the student because they get experience of industry,” says Matt. “It benefits me because I get to access the tools and expertise that industry has. And it benefits the company because they get access to our unique electrophysiology and broader view of mechanisms of cognition.” As part of his MRC Fellowship, Matt will spend time at Lilly’s Centre for Cognitive Neuroscience (CCN, directed by Dr Mark Tricklebank of Lilly), using proprietary technology to study altered sleep states that contribute to cognitive symptoms in schizophrenia. “The Lilly CCN model of jointly supervised postdoctoral Fellows and a broad range of academic collaborations has set a powerful precedent,” he says. “It’s been hugely productive and enjoyable and, alongside academic-industry links, has also fostered new academic collaborations amongst the universities involved.” Matt has also been successful in getting further funding for a collaborative project with Janssen, who will support a PhD student and postdoc in his lab. The University of Bristol is part of the Severnside Alliance for Translational Research (SARTRE), which took part in a pilot scheme whereby they locally managed one of the MRC’s translational research funding schemes: the Developmental Pathway Funding Scheme (DPFS). Through SARTRE , Janssen became interested in psychiatric research in Matt’s lab at Bristol and at the MRC Centre for Neuropsychiatric Genetics and Genomics at Cardiff. Following a one-year pilot, DPFS-funded work contributed to Matt and Professor Lawrence Wilkinson (Cardiff University, also a member of the Lilly CCN) securing an MRC grant to study the neurobiology of a gene linked to schizophrenia . “This is just one example of how a broad network of collaborations spanning industry and academia can fuel future research,” says Matt. Given his success in working with industry, does Matt have any advice for academics who want to follow his lead? “All my industry collaborations have been about answering specific scientific questions that can help people – disregard academic and industrial stereotypes to focus on your common goals and you will certainly find common benefits. The landscape has changed in industry in the last five years, especially in psychiatric research. The business of industrial R&D is always in flux but they know that academic collaborations offer an invaluable knowledge and skills base and – provided the expectations of both parties are realistic – good value for money . Perhaps academics need advertise their wares a little more actively.”